FIELD: pharmaceuticals.
SUBSTANCE: invention relates to a compound represented by general formula (I), or a pharmaceutically acceptable salt thereof, which can be used for the treatment and/or prevention of peripheral neuropathy and/or central neuropathy:
[Formula 1]
where: R1 is (1) -R11-COOR12, (2) -R13-CONR14R15, (3) -R17-CN, (4) -R18-CONHS(O)2-R19, (5) -R20-CycD, or
[Formula 2]
(where: ring 1 represents morpholine and n represents the integer 0); R2 represents (1) a halogen atom or (2) a C1-4 alkyl group, and p is an integer from 0 or 1; X represents either (1) CH2 or (2) an oxygen atom; L1 represents (1) a linear C3-7 alkylene group, which may be substituted by 1-2 RL1a, or (4) (a linear C1-3 alkylene group)-O-(a linear C1-3 alkylene group); R3 represents either (1) a hydrogen atom, (2) a halogen atom, or (4) a C1-2 alkyl group, and q represents an integer from 0 to 2, wherein: when
[Formula 4]
represents a single bond and q is 2, the set of R3 may be the same or different from each other; and when at least one of R3 is a methyl group, the methyl group can form cyclopropane in combination with a carbon atom in adjacent L1 ; CycA is (1) a C6 monocyclic carbocyclic ring or (2) a 5–10 membered monocyclic or bicyclic heterocyclic ring containing a heteroatom selected from an oxygen atom, a nitrogen atom and a sulfur atom; R4 represents (1) a halogen atom, (2) a hydroxyl group, (3) a C1-4 alkyl group, (4) a C1-4 haloalkyl group; (7) a cyano group or (8) a -SO2-C1-2 alkyl group, and r is an integer from 0 to 3, wherein when r is 2 or more, the plurality of R4 may be the same or different from each other; L2 represents -R31-L3-R32-; CycB is (1) a C5-6 monocyclic ring or (2) a 5–10 membered monocyclic or bicyclic heterocyclic ring containing a heteroatom selected from an oxygen atom, a nitrogen atom and a sulfur atom; and R5 represents either (1) a halogen atom, (2) a C1-6 alkyl group, (5) a C1-6 haloalkyl group, or (8) a C1-6 alkoxy group, and t represents the integer 0 or 1, and R11–R20, R31, R32, L3, CycD have the meanings specified in the claims.
EFFECT: production of a compound having neuroprotective and/or neurorestorative activity.
20 cl, 1 dwg, 2 tbl, 273 ex
Title | Year | Author | Number |
---|---|---|---|
8-AZAPROSTAGLANDINE DERIVATIVES, PHARMACEUTICAL COMPOSITION AND AGENT FOR PROPHYLAXIS OF DISEASES | 2003 |
|
RU2306309C2 |
2-PYRIDONE DERIVATIVES | 2010 |
|
RU2551847C2 |
COMPOUNDS WITH AGONISTIC ACTIVITY RELATIVELY TO S1P5 RECEPTOR | 2019 |
|
RU2781541C2 |
PHENYLTETRAHYDROISOQUINOLINE COMPOUND, SUBSTITUTED WITH HETEROARYL | 2015 |
|
RU2703456C2 |
SPLICEOSTATIN ANALOGS | 2013 |
|
RU2618523C2 |
THIAZOLYLPHENYL-BENZENESULFONAMIDO DERIVATIVES AS KINASE INHIBITORS | 2012 |
|
RU2606497C2 |
TETRAHYDROCARBOLINE DERIVATIVE | 2011 |
|
RU2572818C2 |
COMPOUND CAPABLE OF BONDING WITH S1P RECEPTOR AND PHARMACEUTICAL APPLICATION THEREOF | 2004 |
|
RU2390519C2 |
DERIVATIVES OF CARBOXYLIC ACIDS AND PHARMACEUTICAL AGENT COMPRISING THEIR AS ACTIVE COMPONENT | 2002 |
|
RU2315746C2 |
BICYCLIC COMPOUND AND USING IT FOR MEDICAL APPLICATIONS | 2010 |
|
RU2540330C2 |
Authors
Dates
2024-01-17—Published
2019-07-30—Filed